Frost & Sullivan Independent Equity Research
Brainsway Ltd: The Company continues to generate consistent growth based on the rental model with sufficient cash available for 2018; Mild setback in FDA marketing approval (OCD); Price target remains within the forecast range.
![brainsway brainsway](https://www.frostequityresearch.com/wp-content/uploads/elementor/thumbs/brainsway-nx7oepmjwr0nqu046yc3t5fs9jyo1sg30b9j97eox4.png)
Company: Brainsway Ltd.
Sector: Medical Devices
Report type: Q-4 and Annual (2017) Updates
For all past reports click here
Published on: 10 April, 2018